Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Friday, March 29, 2024 · 699,682,439 Articles · 3+ Million Readers

Chronic Obstructive Pulmonary Disease (COPD) Report: Epidemiology Forecast to 2028

/EIN News/ -- Dublin, Jan. 28, 2020 (GLOBE NEWSWIRE) -- The "Chronic Obstructive Pulmonary Disease: Epidemiology Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Epidemiologists utilized county-specific studies published in peer-reviewed journals as well as medical record review studies to build the forecast. The disease definition for COPD was based on symptoms and the results of spirometry testing.

The report includes a 10-year epidemiological forecast for the total prevalent and diagnosed prevalent cases of COPD in the 7MM. Epidemiologists followed the GOLD 2011 and GOLD 2016 criteria for the severity stages of COPD in this forecast across the 7MM.

The following data describes epidemiology of COPD:

In the 7MM, Epidemiologists forecast an increase in the total prevalent cases of COPD from 59,286,188 cases in 2018 to 67,185,113 cases in 2028 at an AGR of 1.33% during the forecast period. In the 7MM, the diagnosed prevalent cases of COPD will increase from 30,733,034 cases in 2018 to 34,561,468 cases in 2028 at an AGR of 1.25% during the forecast period. COPD is more common in older adults. These trends are reflected in forecast for the total prevalent cases, and diagnosed prevalent cases for the 7MM.

Report Scope

  • The Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Report provides an overview of the risk factors and global trends of COPD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of COPD segmented by sex, and age (ages 35 years) in these markets. The diagnosed prevalent cases of COPD are further segmented by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011 as well as GOLD 2016 severity stage (GOLD A, GOLD B, GOLD C, and GOLD D) using the COPD Assessment Test (CAT) scores and the modified Medical Research Council (mMRC) dyspnea scores.
  • The COPD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

The report will allow you to:

  • Develop business strategies by understanding the trends shaping and driving the global COPD market.
  • Quantify patient populations in the global COPD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for COPD therapeutics in each of the markets covered.
  • Understand magnitude of COPD population by severity at diagnosis.

Key Topics Covered

1 Chronic Obstructive Pulmonary Disease (COPD): Executive Summary
1.1 Catalyst
1.2 Related Reports
1.3 Upcoming Reports

2 Epidemiology
2.1 Disease Background
2.2 Risk Factors and Comorbidities
2.3 Global and Historical Trends
2.4 Forecast Methodology
2.4.1 Sources
2.4.2 Forecast Assumptions and Methods
2.5 Epidemiological Forecast for COPD (2018-2028)
2.5.1 Total Prevalent Cases of COPD
2.5.2 Sex-Specific Total Prevalent Cases of COPD
2.5.3 Age-Specific Total Prevalent Cases of COPD
2.5.4 Diagnosed Prevalent Cases of COPD
2.5.5 Sex-Specific Diagnosed Prevalent Cases of COPD
2.5.6 Age-Specific Diagnosed Prevalent Cases of COPD
2.5.7 Diagnosed Prevalent Cases of COPD by Severity
2.6 Discussion
2.6.1 Epidemiological Forecast Insight
2.6.2 Limitations of the Analysis
2.6.3 Strengths of the Analysis

3 Appendix
3.1 Bibliography
3.2 About the Authors
3.2.1 Epidemiologist
3.2.2 Reviewers
3.2.3 Global Director of Therapy Analysis and Epidemiology
3.2.4 Global Head and EVP of Healthcare Operations and Strategy

List of Tables
Table 1: Summary of Newly Added Data Types and Countries
Table 2: Summary of Updated Data Types
Table 3: Risk Factors and Comorbidities for COPD

List of Figures
Figure 1: 7MM, Total Prevalent Cases of COPD, Men and Women, Ages 35 Years, 2018 and 2028
Figure 2: 7MM, Diagnosed Prevalent Cases of COPD, Men and Women, Ages 35 Years, 2018 and 2028
Figure 3: 7MM, Total Prevalence of COPD, Men and Women, Ages 35 Years, 2018
Figure 4: 7MM, Diagnosed Prevalence of COPD, Men and Women, Ages 35 Years, 2018
Figure 5: 7MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of COPD
Figure 6: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of COPD
Figure 7: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of COPD by Severity
Figure 8: 7MM, Total Prevalent Cases of COPD, Men and Women, Ages 35 Years
Figure 9: 7MM, Total Prevalent Cases of COPD, by Sex, Ages 35 Years, 2018
Figure 10: 7MM, Total Prevalent Cases of COPD by Age, Men and Women, 2018
Figure 11: 7MM, Diagnosed Prevalent Cases of COPD, Men and Women, Ages 35 Years
Figure 12: 7MM, Diagnosed Prevalent Cases of COPD, by Sex, Ages 35 Years, 2018
Figure 13: 7MM, Diagnosed Prevalent Cases of COPD by Age, Men and Women, 2018
Figure 14: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using mMRC Scores - GOLD 2011 Criteria), Men and Women, Ages 35 Years, 2018
Figure 15: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using CAT Scores - GOLD 2011 Criteria), Men and Women, Ages 35 Years, 2018
Figure 16: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using mMRC Scores - GOLD 2016 Criteria), Men and Women, Ages 35 Years, 2018
Figure 17: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using CAT Scores - GOLD 2016 Criteria), Men and Women, Ages 35 Years, 2018

For more information about this report visit https://www.researchandmarkets.com/r/jhhaht

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Press Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    

Primary Logo

Powered by EIN News
Distribution channels: Culture, Society & Lifestyle, Science


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release